Dr Boer speaks with ecancer about the genetic subtypes of ALL, and how to best treat BCR-ABL-like patients.
She outlines the network of mutations that can drive leukaemia through JAK, ABL and RAS pathways, and describes Philidelphia-like genetic signatures.
Dr Boer also considers how druggable these pathways may be, including the use of tyrosine kinases.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.